IQVIA Holdings Inc traded at $201.61 this Tuesday July 21st, decreasing $2.29 or 1.12 percent since the previous trading session. Looking back, over the last four weeks, IQVIA Holdings lost 20.14 percent. Over the last 12 months, its price rose by 26.83 percent. Looking ahead, we forecast IQVIA Holdings Inc to be priced at 201.93 by the end of this quarter and at 189.47 in one year, according to Trading Economics global macro models projections and analysts expectations.
IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.